Latest results show that it is facing challenges in Brazil (around 15% revenue).It has recently spent ₹650 cr on Dahej plant.It is spread across the globe with US as key growth driver for future.It has huge growth potential in both API and formulations business where it has presence.The stock is available at reasonable valuations (trailing PE around 12).The company is an API (active pharmaceutical ingredient) and formulations player.Torrent Pharma Research Report by Reader Reader’s Query: This will help her in improving her stock analysis skills. She should learn the interpretation of different types of data and transactions and pay attention to the parts of annual reports etc. In order to benefit the maximum from this article, an investor should focus on the process of analysis instead of looking for good or bad aspects of the company. This article provides an in-depth fundamental analysis of Torrent Pharmaceuticals Limited (Torrent Pharma), an Indian pharmaceutical company focused on lifestyle-related drug segments like Cardiovascular (CVS) and Central Nervous System (CNS).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |